REFERENCES
1. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-410.
2. Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014;72:1938-56.
4. Rogers MJ, Mönkkönen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020;139:115493.
5. Matsumoto T, Endo I. RANKL as a target for the treatment of osteoporosis. J Bone Miner Metab. 2021;39:91-105.
6. Tetradis S, Allen MR, Ruggiero SL. Pathophysiology of medication-related osteonecrosis of the jaw-a minireview. JBMR Plus. 2023;7:e10785.
7. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433-41.
8. Heifetz-Li JJ, Abdelsamie S, Campbell CB, Roth S, Fielding AF, Mulligan JP. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128:491-7.e2.
9. Kim KM, Kim S, Hwang H, et al. Effects of daily versus weekly teriparatide for medication-related osteonecrosis of the jaw: a case-control study. Oral Dis. 2024;30:3286-95.
10. Katagiri T, Watabe T. Bone morphogenetic proteins. Cold Spring Harb Perspect Biol. 2016;8:a021899.
11. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem. 1996;237:295-302.
12. Irie A, Habuchi H, Kimata K, Sanai Y. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun. 2003;308:858-65.
13. Takada T, Katagiri T, Ifuku M, et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem. 2003;278:43229-35.
14. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467-73.
15. Arksey H, O’malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19-32.
16. Durieux N, Vandenput S, Pasleau F. [OCEBM levels of evidence system]. Rev Med Liege. 2013;68:644-9.
17. Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.5. Cochrane; 2024. Available from: https://training.cochrane.org/handbook. [Last accessed on 27 Apr 2025].
18. Colapinto G, Goker F, Nocini R, et al. Outcomes of a pharmacological protocol with pentoxifylline and tocopherol for the management of medication-related osteonecrosis of the jaws (MRONJ): a randomized study on 202 osteoporosis patients. J Clin Med. 2023;12:4662.
19. Fernandes TL, Viezzer Fernandes B, Franco GCN. Treatment of medication-related osteonecrosis of the jaws without segmental resections: a case series. Am J Case Rep. 2024;25:e942980.
20. Magalhães JMI, da Motta Silveira FM, Regueira LS, de Lima E Silva DF, de Andrade Veras SR, de Mello MJG. Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series. Support Care Cancer. 2023;31:462.
21. Martin K, Nathwani S, Bunyan R. Medication related osteonecrosis of the jaw: an adjunctive medical regime. Oral Surgery. 2018;11:266-72.
22. Owosho AA, Estilo CL, Huryn JM, Yom SK. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:455-9.
23. Słowik Ł, Totoń E, Nowak A, Wysocka-Słowik A, Okła M, Ślebioda Z. Pharmacological treatment of medication-related osteonecrosis of the jaw (MRONJ) with pentoxifylline and tocopherol. J Clin Med. 2025;14:974.
24. Varoni EM, Lombardi N, Villa G, Pispero A, Sardella A, Lodi G. Conservative management of medication-related osteonecrosis of the jaws (MRONJ): a retrospective cohort study. Antibiotics. 2021;10:195.
25. Jung J, Yoo HY, Kim GT, et al. Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study. J Bone Miner Res. 2017;32:2445-52.
26. Kim MS, Kim KJ, Kim BJ, Kim CH, Kim JH. Immediate reconstruction of mandibular defect after treatment of medication-related osteonecrosis of the jaw (MRONJ) with rhBMP-2/ACS and miniplate: review of 3 cases. Int J Surg Case Rep. 2020;66:25-9.
27. Park JH, Kim JW, Kim SJ. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2017;75:1176-84.
28. Rahim I, Salt S, Heliotis M. Successful long-term mandibular reconstruction and rehabilitation using non-vascularised autologous bone graft and recombinant human BMP-7 with subsequent endosseous implant in a patient with bisphosphonate-related osteonecrosis of the jaw. Br J Oral Maxillofac Surg. 2015;53:870-4.
29. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
30. Srivastava A, Nogueras Gonzalez GM, Geng Y, et al. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2021;29:2305-17.
31. Sultan A, Hanna GJ, Margalit DN, et al. The use of hyperbaric oxygen for the prevention and management of osteoradionecrosis of the jaw: a Dana-Farber/Brigham and women’s cancer center multidisciplinary guideline. Oncologist. 2017;22:343-50.
32. Grisar K, Schol M, Schoenaers J, et al. Osteoradionecrosis and medication-related osteonecrosis of the jaw: similarities and differences. Int J Oral Maxillofac Surg. 2016;45:1592-9.
33. Li Z, Fu R, Huang X, Wen X, Zhang L. Oral microbiota may affect osteoradionecrosis following radiotherapy for head and neck cancer. J Transl Med. 2023;21:391.
34. Choi NR, Na HS, Han H, Chung J, Kim YD. Next-generation sequencing analysis of bacterial species present in the sequestrum of medication-related osteonecrosis of the jaw patients. Arch Oral Biol. 2025;172:106180.
35. Bell DSH. Are the protean effects of pentoxifylline in the therapy of diabetes and its complications still relevant? Diabetes Ther. 2021;12:3025-35.
36. Marjanowski SD, Maldonado A, Schaller B, Burkhard JM. [Pentoxifylline and tocopherol - the importance in the treatment of osteoradionecrosis - literature review and case report]. Swiss Dent J. 2021;131:713-8.
37. Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2020;10:CD005262.
38. Martos-Fernández M, Saez-Barba M, López-López J, Estrugo-Devesa A, Balibrea-Del-Castillo JM, Bescós-Atín C. Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:431-9.
39. Cavalcante RC, Tomasetti G. Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: a systematic literature review. J Craniomaxillofac Surg. 2020;48:1080-6.
40. Lyons AJ, Brennan PA. Pentoxifylline - a review of its use in osteoradionecrosis. Br J Oral Maxillofac Surg. 2017;55:230-4.
41. Peng WX, Wang L. Adenovirus-mediated expression of BMP-2 and BFGF in bone marrow mesenchymal stem cells combined with demineralized bone matrix for repair of femoral head osteonecrosis in beagle dogs. Cell Physiol Biochem. 2017;43:1648-62.
42. Bian Y, Hu T, Lv Z, et al. Bone tissue engineering for treating osteonecrosis of the femoral head. Exploration. 2023;3:20210105.
43. Zhu H, Shi Z, Cai X, Yang X, Zhou C. The combination of PLLA/PLGA/PCL composite scaffolds integrated with BMP-2-loaded microspheres and low-intensity pulsed ultrasound alleviates steroid-induced osteonecrosis of the femoral head. Exp Ther Med. 2020;20:126.
44. Beederman M, Lamplot JD, Nan G, et al. BMP signaling in mesenchymal stem cell differentiation and bone formation. J Biomed Sci Eng. 2013;6:32-52.
45. Wu Z, Bao C, Zhou S, et al. The synergetic effect of bioactive molecule-loaded electrospun core-shell fibres for reconstruction of critical-sized calvarial bone defect-the effect of synergetic release on bone formation. Cell Prolif. 2020;53:e12796.
46. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40:1434-46.
47. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
48. Brixen KT, Christensen PM, Ejersted C, Langdahl BL. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol. 2004;94:260-70.
